Abstract
The weight loss drug semaglutide (Wegovy) is now approved for pediatric patients ages 12 and older whose body mass index categorizes them as obese.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
MeSH terms
-
Anti-Obesity Agents* / adverse effects
-
Child
-
Diabetes Mellitus, Type 2*
-
Glucagon-Like Peptides / therapeutic use
-
Humans
-
Hypoglycemic Agents / adverse effects
Substances
-
semaglutide
-
Hypoglycemic Agents
-
Anti-Obesity Agents
-
Glucagon-Like Peptides